Take Limited delivered a consolidated net profit of ₹106.26 lakhs (₹1.06 crore) for the quarter ended June 30, 2026 (Q1FY27), marking a decisive return to profitability from a net loss of ₹91.00 lakhs in Q1FY26. The Chennai-based healthcare technology company reported consolidated revenue from operations of ₹3,037.33 lakhs (₹30.37 crore), expanding significantly from nil revenue in the corresponding period last year. This turnaround was primarily driven by operational scaling and a drastic reduction in finance costs, which fell 99.62% year-on-year to just ₹0.07 lakhs, reflecting a cleaner capital structure.

The Board of Directors approved the unaudited standalone and consolidated financial results on August 11, 2026, in compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results were reviewed by A. Raghavendra Rao & Associates, the statutory auditors, who issued a limited review report confirming that the financial statements present a true and fair view in accordance with Ind AS 34. The company, formerly known as Take Solutions Limited, has also announced a strategic entry into the longevity and biohacking sector, leveraging its clinical research expertise.

Financial Performance Highlights

Standalone performance mirrored the consolidated results, with revenue from operations rising to ₹1,196.90 lakhs from ₹0.65 lakhs in Q1FY26. Standalone net profit turned positive at ₹96.83 lakhs, compared to a loss of ₹216.45 lakhs previously. Total income for the consolidated entity reached ₹3,170.11 lakhs, supported by other income of ₹132.78 lakhs. Basic and diluted earnings per share (EPS) turned positive at ₹0.07 per share, up from negative ₹0.06 per share in Q1FY26.

Strategic Shift to Longevity Market

Management highlighted the stabilization of the operational framework as a key enabler for future growth. Parmeshvar Dhangare, Chairman & Director, stated that the clean balance sheet and near-zero finance costs position the company to execute its next growth phase. The firm is targeting the global longevity market, projected to grow from USD 27.61 billion in 2025 to USD 67.03 billion by 2035. In India, the preventive healthcare market reached USD 197 billion in 2025, with anti-aging supplements expected to expand at a 9.5% CAGR through 2033. The strategy involves integrating science-backed nutraceuticals with digital tools for metabolic health tracking.

What the Numbers Show

The most striking aspect of the Q1FY27 results is the complete reversal of the cost structure regarding debt servicing. Finance costs plummeted from ₹17.50 lakhs to ₹0.07 lakhs, indicating either debt repayment or refinancing at negligible rates. This reduction directly contributed to the bottom-line turnaround, as operating expenses remained relatively controlled. While revenue generation is new for this quarter (nil in Q1FY26), the ability to generate ₹106.26 lakhs in net profit on ₹3,037.33 lakhs of revenue suggests an initial gross margin advantage, though sustainability will depend on scaling this model without proportional increases in employee benefits or other expenses, which currently stand at ₹7.40 lakhs and ₹29.58 lakhs respectively.

Take Solutions has initiated a postal ballot process to seek shareholder approval for the appointment of Mr. Sunil Patra as Managing Director of the company for a period of five years. The appointment, effective from May 19, 2026, to May 18, 2031, requires member consent pursuant to Regulation 17(1C) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company reported a significant financial turnaround in the fiscal year ended March 31, 2026, which serves as a backdrop for this leadership appointment.

The board approved the resolution during its meeting on May 19, 2026, recommending the appointment based on Mr. Patra's experience in operational management and financial coordination. The remuneration proposed is up to ₹5,00,000 per annum on a Cost to Company basis, along with perquisites and commission subject to board approval. The company has engaged Central Depository Services (India) Limited (CDSL) to facilitate the remote e-voting process.

Postal Ballot Schedule

The remote e-voting facility is available to shareholders whose names appear in the Register of Members as of Friday, July 03, 2026. The process commenced on Thursday, July 16, 2026, at 9:00 am and will conclude on Friday, August 14, 2026, at 5:00 pm. M/s. Hemang Satra & Associates, Company Secretaries, has been appointed as the scrutinizer to ensure the integrity of the voting process.

Financial Performance Context

The company's explanatory statement highlights a substantial improvement in financial performance for the year ended March 31, 2026. On a standalone basis, Total Income rose to ₹661.75 Lakhs, and the company reported a Net Profit of ₹271.91 Lakhs, compared to a Net Loss of ₹6,973.56 Lakhs in the previous fiscal year ended March 31, 2025. This turnaround is attributed to strengthened business operations and enhanced governance standards.

Shareholders can cast their votes through the CDSL e-voting system or via physical postal ballot forms. The results of the postal ballot will be declared within two working days from the conclusion of the e-voting period and will be communicated to the stock exchanges.